GPT and neutropenia: The most common grade ≥3 AEs (≥10%) with asciminib were thrombocytopenia (22.4%) and neutropenia (18.6%) and with bosutinib were neutropenia (14.5%), diarrhea (10.5%), and increased alanine aminotransferase (ALT) (14.5%) (Table 2).